DiaMedica Therapeutics Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report. DiaMedica is a British Columbia clinical-stage biopharmaceutical company listed on Nasdaq under DMAC.
Business context
DiaMedica is developing DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 protein, primarily for acute ischemic stroke (AIS) and cardio-renal disease (CRD). DM300, a potential treatment for severe inflammatory diseases, remains in early preclinical development. The Company has no approved products and has generated no product-sales revenue.
The principal development program is the Phase 2/3 adaptive ReMEDy2 trial of DM199 in AIS. The trial is designed to enroll approximately 350 patients at up to 100 global sites, with treatment within 24 hours of symptom onset and a day-90 modified Rankin Scale endpoint.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No product sales |
| Research and development expense | $13.1 million | $7.8 million | Increased $5.3 million |
| General and administrative expense | $8.2 million | $6.2 million | Increased $2.0 million |
| Total operating expenses | $21.3 million | $14.0 million | Increased $7.3 million |
| Other income, net | $1.9 million | $0.4 million | Higher interest income |
| Net loss | $19.4 million | $13.7 million | Loss increased $5.7 million |
| Net loss per share | $0.60 | $0.52 | Loss per share increased |
| Cash flow used in operations | $18.7 million | $11.5 million | Use increased $7.2 million |
Operating margin and gross margin are not meaningful because the Company has no product revenue. The accumulated deficit was $115.6 million at December 31, 2023.
Liquidity, capital structure and commitments
- Cash, cash equivalents and marketable securities totaled $52.9 million at December 31, 2023, compared with $33.5 million at year-end 2022.
- Cash and cash equivalents alone were $4.5 million; marketable securities were $48.4 million.
- Working capital was $50.9 million, total assets were $54.2 million and total shareholders’ equity was $51.1 million.
- Total current liabilities were $2.8 million. The Company reported no existing credit facilities and no material funded debt; lease obligations were approximately $0.4 million in total.
- Financing activities provided $36.8 million in 2023, principally from April and June private placements. The June placement issued 11.0 million common shares at $3.40 per share, or $3.91 per share for participating directors and officers, and generated approximately $36.1 million of net proceeds.
- Shares outstanding increased to 37.96 million at December 31, 2023 from 26.44 million at year-end 2022, creating material dilution for existing shareholders.
- Estimated outstanding clinical, manufacturing and related commitments were approximately $15.3 million over the next 12 months and $12.5 million in the subsequent 12 months. Remaining operating lease obligations totaled approximately $396,000.
Material changes versus 2022
- R&D spending increased primarily because of ReMEDy2 clinical-hold response activities, in-use studies, the Phase 1C safety study, manufacturing and process development, and higher clinical personnel costs.
- G&A spending rose due mainly to legal fees related to the PRA Netherlands litigation, increased personnel costs, patent prosecution and share-based compensation.
- Interest income increased substantially because of higher interest rates and larger marketable-securities balances.
- Cash resources and shareholders’ equity increased primarily because of the 2023 equity financings, partially offset by operating cash burn.
- The FDA lifted the clinical hold on the ReMEDy2 IND in June 2023. The Company amended the protocol, including reducing the initial IV dose, and proceeded under the amended protocol after the FDA’s 30-day review period ended November 3, 2023 without comments.
- The Company added a Chief Business Officer in 2023 and appointed a new Chief Medical Officer in January 2024. Headcount was 19 employees as of December 31, 2023.
Clinical progress, outlook and risks
The ReMEDy2 trial had been paused after three unexpected, clinically significant transient hypotension events. The Company believes the events were associated with a change in IV bag materials that may have increased delivered DM199 exposure. The events resolved within minutes after stopping infusion and caused no reported injuries. A Phase 1C study, including patients receiving ACE inhibitors, reported no instances of hypotension at the proposed 0.5 microgram/kg IV dose.
Management’s near-term priorities are to resume and globally expand ReMEDy2, advance manufacturing process development, determine next steps for the CRD program in 2024, and identify strategic partners for further development and commercialization. The filing does not provide a clear enrollment, site-activation or trial-completion timetable.
- The Company expects its current cash resources to fund planned operations and ReMEDy2 for at least 12 months from the issuance of the financial statements, but expects substantial additional capital will be required.
- Management expects operating losses and negative cash flow to continue for at least the next several years and does not expect product-sales revenue for at least three or four years, if ever.
- Future financing may be raised through equity, debt, collaborations or licenses. Equity financing would dilute shareholders; collaboration or licensing transactions could require relinquishing valuable rights.
- Key risks include clinical failure or delay, renewed regulatory holds, slow site activation or patient enrollment, adaptive-trial enrollment expansion, hypotension or other safety events, reliance on contract research organizations and Catalent for manufacturing, regulatory approval uncertainty, reimbursement and market-acceptance risk, intellectual-property challenges, and dependence on additional financing.
- The Company believes it was a passive foreign investment company for 2022 and 2023, which may create adverse U.S. tax consequences for certain U.S. shareholders.
- The Company reported ongoing litigation concerning missing clinical-study records and alleged execution failures by PRA Netherlands. In February 2024, the Netherlands Commercial Court confirmed DiaMedica’s ownership of the records but found an insufficient causal link to the damages claimed. DiaMedica had approximately 90 days from that decision to evaluate an appeal.
Most important facts for investors to verify
- ReMEDy2 enrollment, active sites, interim-analysis timing and whether the amended protocol resolves prior safety and operational issues.
- Cash burn relative to the $52.9 million liquidity balance, including the effect of the $27.8 million of estimated near-term and following-year commitments.
- Timing and terms of any additional financing, collaboration or licensing transaction, and resulting dilution or loss of economic rights.
- Clinical efficacy and safety results for DM199, particularly the frequency and severity of hypotension and the statistical strength of ReMEDy2 outcomes.
- Regulatory requirements and approval probability for DM199 in AIS and CRD; Fast Track designation does not assure approval.
- Manufacturing capacity, supply continuity and the commercial implications of the PVC IV-bag formulation.
- Potential financial recovery, further proceedings and timing related to the PRA Netherlands litigation.
- PFIC status and related U.S. tax reporting obligations for affected shareholders.